Stahist Ad Tablet
NDC Package 58407-625-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Stahist Ad (chlorcyclizine hydrochloride and pseudoephedrine hydrochloride) tablets is do not exceed recommended dosage.Adults and children 12 years of age and over:1 tablet by mouth every 6-8 hours, not to exceed 3 tablets in 24 hours, or as directed by a doctorChildren 6 to under 12 years of age:½ tablet by mouth every 6-8 hours, not to exceed 1½ tablets in 24 hours, or as directed by a doctorChildren under 6 years of ageConsult a doctor. This formulation utilizes a tablet delivery system. Marketed by Magna Pharmaceuticals, Inc., this product is identified by NDC 58407-625 and is authorized under FDA application M012.

Identification & Billing

NDC Package Code
58407-625-06
Package Description
6 BLISTER PACK in 1 BOX / 1 TABLET in 1 BLISTER PACK (58407-625-01)
Product Code
58407-625
11-Digit Billing Format
58407062506
RxNorm Crosswalk
  • RxCUI: 1235861 - chlorcyclizine HCl 25 MG / pseudoephedrine HCl 60 MG Oral Tablet
  • RxCUI: 1235861 - chlorcyclizine hydrochloride 25 MG / pseudoephedrine hydrochloride 60 MG Oral Tablet
  • RxCUI: 1236716 - Stahist AD 25 MG / 60 MG Oral Tablet
  • RxCUI: 1236716 - chlorcyclizine hydrochloride 25 MG / pseudoephedrine hydrochloride 60 MG Oral Tablet [Stahist AD]
  • RxCUI: 1236716 - Stahist AD (chlorcyclizine hydrochloride 25 MG / pseudoephedrine hydrochloride 60 MG) Oral Tablet

Clinical Specifications

Proprietary Name
Stahist Ad
Non-Proprietary Name
Chlorcyclizine Hydrochloride And Pseudoephedrine Hydrochloride
Substance Name
Chlorcyclizine Hydrochloride; Pseudoephedrine Hydrochloride
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Do not exceed recommended dosage.Adults and children 12 years of age and over:1 tablet by mouth every 6-8 hours, not to exceed 3 tablets in 24 hours, or as directed by a doctorChildren 6 to under 12 years of age:½ tablet by mouth every 6-8 hours, not to exceed 1½ tablets in 24 hours, or as directed by a doctorChildren under 6 years of ageConsult a doctor

Regulatory & Marketing

Labeler Name
Magna Pharmaceuticals, Inc.
Product Type
Human Otc Drug
FDA Application #
M012
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
12-20-2011
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (58407-625). Click a package code to view its specific billing and regulatory data.

58407-625-01
1 TABLET in 1 BLISTER PACK
58407-625-30
1 BOTTLE in 1 BOX / 30 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58407-625-06 identifies a specific commercial package of 6 blister pack in 1 box / 1 tablet in 1 blister pack (58407-625-01) of Stahist Ad, a human over the counter drug labeled by Magna Pharmaceuticals, Inc.. This tablet is formulated for oral use and contains chlorcyclizine hydrochloride; pseudoephedrine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Magna Pharmaceuticals, Inc. on December 20, 2011. The current certification is valid through December 31, 2026.

How is this Magna Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58407062506. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
58407-625-06
11-Digit CMS (5-4-2)
58407-0625-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.